News | Biogen

October 13, 2021

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosing Real-world analysis shows significantly lower risk of relapse for patients treated with TYSABRI ® compared to Ocrevus ® (ocrelizumab) New

October 13, 2021

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

October 6, 2021

Biogen to Report Third Quarter 2021 Financial Results October 20, 2021

List View Grid View

April 29, 2019

Biogen Announces Three New Nominees for Election to Board of Directors

Nominees Bring Decades of Management and Global Operating Experience, Including at Leading Healthcare Companies CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced the nomination of John R. Chiminski, William A. Hawkins and Jesus B.

April 12, 2019

Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference

Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an unmet medical need Infants with pre-symptomatic SMA treated with SPINRAZA® (nusinersen) achieve motor milestones that are

March 27, 2019

Biogen to Present at the Stifel First Annual CNS Day

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen, will present at the Stifel First Annual CNS Day. The webcast will be live on Monday, April 1, at 12:00 p.m. ET.

March 21, 2019

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the

March 13, 2019

Biogen to Report First Quarter 2019 Financial Results April 24, 2019

Cambridge, MA, — Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2019 financial results Wednesday, April 24, 2019, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

March 12, 2019

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

Approximately 800 employees at Hillerød site expected to continue employment under Fujifilm ownership Biogen will enter into manufacturing services agreements with Fujifilm to supply TYSABRI ® and third-party products Biogen expects new manufacturing facility in Solothurn, Switzerland to be

March 5, 2019

Biogen to Present at the Cowen 39th Annual Health Care Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that it will present at the Cowen 39th Annual Health Care Conference. The webcast will be live on Monday, March 11, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/ .

March 4, 2019

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness Nightstar has two potentially first-in-class mid-

February 28, 2019

Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease SPINRAZA was approved under the China National Medical Products Association priority review process evaluating therapies with urgent clinical needs Over

February 25, 2019

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral